{"disease":{"id":"retinitis","name":"retinitis"},"drugs":{"marketed":[{"drug_id":"prednisone","indication_name":"Chorioretinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Chorioretinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"foscarnet","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"foscarnet","indication_name":"CMV Retinitis Relapse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"sulfadiazine","indication_name":"Chorioretinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfadiazine","generic_name":"SULFADIAZINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"valganciclovir","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valcyte","generic_name":"VALGANCICLOVIR","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Valcyte works by inhibiting the replication of cytomegalovirus DNA through its action as a nucleoside analog DNA polymerase inhibitor."},{"drug_id":"cidofovir","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vistide","generic_name":"CIDOFOVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"cidofovir","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"ganciclovir","indication_name":"CMV Retinitis in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"ganciclovir","indication_name":"Cytomegaloviral retinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"fomivirsen","indication_name":"Cytomegaloviral retinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FOMIVIRSEN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"fomivirsen","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"foscarnet","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"vistide","indication_name":"CMV Retinitis in AIDS Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vistide","company_name":"Gustave Roussy, Cancer Campus, Grand Paris","drug_phase":"marketed","molecular_target":"DNA polymerase catalytic subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":13,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00378742","title":"Repository for Inherited Eye Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":6618,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT03753893","title":"Ocular Manifestations in Rheumatic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT00231010","title":"Molecular Genetics of Retinal Degenerations","phase":"","overall_status":"COMPLETED","enrollment_count":3549,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT00001734","title":"Screening for NEI Clinical Studies","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT05589714","title":"Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Jaeb Center for Health Research","has_results":false},{"nct_id":"NCT04620876","title":"Bimodal and Coaxial High Resolution Ophtalmic Imaging","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","has_results":false},{"nct_id":"NCT04128150","title":"High Resolution Retina Imaging","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","has_results":false},{"nct_id":"NCT06092346","title":"A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":999,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT01432847","title":"Cell Collection to Study Eye Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":930,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT04723160","title":"Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph","phase":"","overall_status":"COMPLETED","enrollment_count":748,"lead_sponsor_name":"Visionary Intelligence Ltd.","has_results":false},{"nct_id":"NCT04141891","title":"Advancing Understanding of Transportation Options","phase":"NA","overall_status":"COMPLETED","enrollment_count":529,"lead_sponsor_name":"University of Colorado, Denver","has_results":true},{"nct_id":"NCT02617966","title":"Rod and Cone Mediated Function in Retinal Disease","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT00559234","title":"Potential Research Participants for Future Studies of Inherited Eye Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT03584165","title":"Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":330,"lead_sponsor_name":"NightstaRx Ltd, a Biogen Company","has_results":false},{"nct_id":"NCT00106743","title":"Natural History and Genetic Studies of Usher Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":249,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT04926129","title":"Natural History of the Progression of X-Linked Retinitis Pigmentosa","phase":"","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"NightstaRx Ltd, a Biogen Company","has_results":false},{"nct_id":"NCT02014389","title":"Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT06982417","title":"InsightRP2 Registry","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Göttingen","has_results":false},{"nct_id":"NCT07265895","title":"Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT03349242","title":"Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)","phase":"","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"MeiraGTx UK II Ltd","has_results":false},{"nct_id":"NCT06388200","title":"A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Ocugen","has_results":false},{"nct_id":"NCT05413148","title":"The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":135,"lead_sponsor_name":"TC Erciyes University","has_results":false},{"nct_id":"NCT07056738","title":"Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":130,"lead_sponsor_name":"University Medical Center Goettingen","has_results":false},{"nct_id":"NCT03901391","title":"Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Sensor Technology for Deafblind","has_results":false},{"nct_id":"NCT07082855","title":"A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT05793515","title":"Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models","phase":"","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Istituto Superiore di Sanità","has_results":false},{"nct_id":"NCT06375239","title":"Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Ray Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03975543","title":"Retrospective Natural History Study of Retinitis Pigmentosa","phase":"","overall_status":"UNKNOWN","enrollment_count":113,"lead_sponsor_name":"SparingVision","has_results":false},{"nct_id":"NCT04671433","title":"Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04127006","title":"Rate of Progression in EYS Related Retinal Degeneration","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":103,"lead_sponsor_name":"Jaeb Center for Health Research","has_results":false},{"nct_id":"NCT01680510","title":"The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT05335746","title":"Ocular Changes in Vitiligo Patients on Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Benha University","has_results":false},{"nct_id":"NCT05355415","title":"Adaptive Optics Imaging of Outer Retinal Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Food and Drug Administration (FDA)","has_results":false},{"nct_id":"NCT04245072","title":"Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"The Filatov Institute of Eye Diseases and Tissue Therapy","has_results":false},{"nct_id":"NCT04794101","title":"Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":97,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06368375","title":"Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa","phase":"","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"University Hospital Tuebingen","has_results":false},{"nct_id":"NCT04448860","title":"Validation of Standardized Test Protocols to Assess the Impact of Visual Pathologies in Daily Life Activities","phase":"NA","overall_status":"UNKNOWN","enrollment_count":87,"lead_sponsor_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","has_results":false},{"nct_id":"NCT04850118","title":"A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Beacon Therapeutics","has_results":false},{"nct_id":"NCT03073733","title":"Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"jCyte, Inc","has_results":true},{"nct_id":"NCT04285398","title":"Prospective Natural History Study of Retinitis Pigmentosa","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":82,"lead_sponsor_name":"SparingVision","has_results":false},{"nct_id":"NCT05800301","title":"Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Ankara Universitesi Teknokent","has_results":false},{"nct_id":"NCT00447980","title":"A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Neurotech Pharmaceuticals","has_results":true},{"nct_id":"NCT00447993","title":"A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Neurotech Pharmaceuticals","has_results":true},{"nct_id":"NCT04909398","title":"Pupil Dynamics and Color Vision for the Detection of Eye Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","has_results":false},{"nct_id":"NCT04252534","title":"Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Ankara Universitesi Teknokent","has_results":false},{"nct_id":"NCT04525261","title":"Natural History of Patients With Inherited Retinal Diseases Due to Mutations in RPE65 Gene","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"University of Campania Luigi Vanvitelli","has_results":false},{"nct_id":"NCT05809635","title":"Study of BEST1 Vitelliform Macular Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03116113","title":"A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT05573984","title":"Natural History of PRPF31 Mutation-Associated Retinal Dystrophy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"PYC Therapeutics","has_results":false},{"nct_id":"NCT07408232","title":"A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Octant, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}